1. Home
  2. QVCG vs GALT Comparison

QVCG vs GALT Comparison

Compare QVCG & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QVC Group Inc. Common Stock

QVCG

QVC Group Inc. Common Stock

SELL

Current Price

$8.20

Market Cap

377.0M

ML Signal

SELL

Logo Galectin Therapeutics Inc.

GALT

Galectin Therapeutics Inc.

SELL

Current Price

$3.07

Market Cap

397.3M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
QVCG
GALT
Founded
1991
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
377.0M
397.3M
IPO Year
2026
2008

Fundamental Metrics

Financial Performance
Metric
QVCG
GALT
Price
$8.20
$3.07
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 195.8K
182.3K
Earning Date
11-16-2026
11-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 36.84
EPS
★ 0.76
N/A
Revenue
★ $8,293,000,000.00
N/A
Revenue This Year
$9.11
N/A
Revenue Next Year
$55.29
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$6.80
$2.03
52 Week High
$18.32
$7.13

Technical Indicators

Market Signals
Indicator
QVCG
GALT
Relative Strength Index (RSI) 40.25 39.66
Support Level $6.80 $2.74
Resistance Level $8.59 $3.30
Average True Range (ATR) 0.68 0.29
MACD 0.29 -0.01
Stochastic Oscillator 77.78 19.37

Price Performance

Historical Comparison
QVCG
GALT

About QVCG QVC Group Inc. Common Stock

QVC Group Inc is a live social shopping company with six retail brands: QVC, HSN, Ballard Designs, Frontgate, Garnet Hill, and Grandin Road, and other minority interests. The group is redefining the shopping experience through video-driven commerce on every screen, from smartphones and tablets to laptops and TVs. It brings products, compelling content, and unforgettable moments to millions of shoppers world-wide.

About GALT Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Share on Social Networks: